title: [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
abstract: Parathyroid hormone (PTH) acts as an anabolic agent and is used for the treatment for osteoporosis. Daily or once-weekly self-administered subcutaneous injection of human PTH (1-34) (teriparatide) increased bone mineral density (BMD) compared to a placebo in post-menopausal osteoporotic patients. Recently, data have accumulated that collagen cross-link formation in bone affect bone strength. In fact, impaired enzymatic cross-linking and/or an increase in non-enzymatic cross-links, pentosidine, which is a surrogate marker of advanced glycation end products (AGEs) , in bone collagen have been proposed as a major cause of bone fragility in osteoporosis. We reported that teriparatide improves bone collagen cross-link formation, microarchitecture, and bone mass, resulting in the increase of bone strength (Saito M : Osteoporos Int 22 : 2373-83, 2011) . In this review, we described how teriparatide improve bone collagen cross-link formation and mineral qualities.
authors.affiliation: Department of Orthopaedic Surgery, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Saito
authors.forename: Keishi
authors.initials: K
authors.lastname: Marumo
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001842:Bone and Bones / Q000378:metabolism* / Q000648:ultrastructure; D003094:Collagen / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism*; D019379:Teriparatide / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide; D003094:Collagen